NASDAQ$LFST
LifeStance Health Group Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
LifeStance reported a 22% increase in Q4 revenue, driven by clinician growth, visit volumes, and revenue per visit.
LifeStance Health Group, Inc. announced its Q4 2023 financial results, featuring a 22% increase in revenue to $280.6 million. The company's clinician base grew by 18%, with visit volumes up by 20%. Despite a net loss of $45.0 million, adjusted EBITDA was positive at $20.3 million. The company is focused on operational improvements and profitable growth.
- Q4 revenue increased by 22% to $280.6 million.
- Clinician base increased by 18% to 6,645 clinicians.
- Visit volumes increased by 20% to 1.8 million.
- Adjusted EBITDA increased 99% to $20.3 million.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$281M
Forward guidance
LifeStance expects full year 2024 revenue of $1.19 billion to $1.24 billion, Center Margin of $345 to $365 million, Adjusted EBITDA of $80 to $90 million, and positive Free Cash Flow.
Tailwinds
- Expecting full year 2024 revenue of $1.19 billion to $1.24 billion
- Center Margin of $345 to $365 million
- Adjusted EBITDA of $80 to $90 million
- Expecting positive Free Cash Flow for the full year
- Focus on operational improvements, profitable growth, and disciplined capital deployment
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro